News Release

Co-Diagnostics, Inc. to Present at the Fourth Annual Robins Equity Research Roundup

SALT LAKE CITY--(BUSINESS WIRE)--Sep. 20, 2018-- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that it will be presenting at the Fourth Annual Robins Equity Research Roundup, held September 25 – 26, 2018 near Portland, Oregon.

The Equity Research Roundup is sponsored by Catalyst Research Management Group, RIA, to offer opportunities for portfolio, hedge, and mutual fund managers, individual investors, and retail brokers to become acquainted with up-and-coming public and private companies. In addition to company presentations from a range of industries, the conference will also facilitate company introductions to influential members of the investment community. Co-Diagnostics CEO Dwight Egan will be presenting at 10:30 AM PDT on September 25th.

Mr. Egan remarked: “We are excited to return to the Equity Research Roundup and to share the progress we have made since our presentation a year ago. We believe that Marc Robins’ experience advocating for public micro-cap companies and experience in bringing them together with notable members of the investment world will facilitate telling our story to that community.”

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Source: Co-Diagnostics, Inc.

Company Contact:
Co-Diagnostics Investor Relations
Andrew Benson, 801-438-1036
investors@codiagnostics.com
or
Investor Contact:
Lytham Partners, LLC
Joe Diaz, Robert Blum and Joe Dorame
602-889-9700